Sandra Horning, MD
The combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) reduced the risk of disease progression or death versus obinutuzumab plus chlorambucil in treatment-naïve patients with chronic lymphocytic leukemia (CLL) with comorbidities.
Several patients experienced serious grade 3 or 4 adverse events, with neutropenia being the most common (38.5%). Although no clinical TLS was reported, 2 patients developed laboratory TLS. Neither event, however, resulted in treatment delays or dose modification.
Fischer K, Fink A-M, Bishop H, et al. Results of the Safety Run-in Phase of CLL14 (BO25323): A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare the Efficacy and Safety of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) with Obinutuzumab and Chlorambucil in Patients with Previously Untreated CLL and Coexisting Medical Conditions. Presented at: 57th American Society of Hematology Annual Meeting; Orlando, Florida; December 5-8, 2015. Abstract 496.
... to read the full story